Latest & greatest articles for multiple sclerosis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on multiple sclerosis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on multiple sclerosis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for multiple sclerosis

61. Multiple sclerosis: a drug that should never have been authorised

Multiple sclerosis: a drug that should never have been authorised Prescrire IN ENGLISH - Spotlight ''Multiple sclerosis: a drug that should never have been authorised'', 1 July 2018 {1} {1} {1} | | > > > Multiple sclerosis: a drug that should never have been authorised Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |   |   |  Spotlight Multiple sclerosis: a drug (...) that should never have been authorised In March 2018, after several deaths, daclizumab (Zinbryta°) was withdrawn from the market. The European Medicines Agency should never have authorised this drug. In patients with multiple sclerosis, interferon beta is the first-choice treatment, for want of a better option. Despite the severity of multiple sclerosis in some patients, there is no justification for exposing them to drugs such as alemtuzumab, natalizumab or teriflunomide, whose harm-benefit balance

2018 Prescrire

62. Beta interferons and glatiramer acetate for treating multiple sclerosis

Beta interferons and glatiramer acetate for treating multiple sclerosis Beta interferons and glatir Beta interferons and glatiramer acetate amer acetate for treating multiple sclerosis for treating multiple sclerosis T echnology appraisal guidance Published: 27 June 2018 nice.org.uk/guidance/ta527 © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations (...) and to reduce health inequalities. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Beta interferons and glatiramer acetate for treating multiple sclerosis (TA527) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 29Contents Contents 1

2018 National Institute for Health and Clinical Excellence - Technology Appraisals

63. Teriflunomide (Aubagio) - relapsing remitting multiple sclerosis (RRMS)

Teriflunomide (Aubagio) - relapsing remitting multiple sclerosis (RRMS) Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Expand all Summary Basis of Decision (SBD) for Contact: Summary Basis of Decision (SBD) documents provide information related to the original authorization of a product. The for is located below. Recent Activity for SBDs written for approved

2018 Health Canada - Drug and Health Product Register

64. Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology Full Text available with Trip Pro

Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology To develop recommendations for disease-modifying therapy (DMT) for multiple sclerosis (MS).A multidisciplinary panel developed DMT recommendations, integrating findings from a systematic review; followed an Institute of Medicine-compliant process to ensure transparency

2018 EvidenceUpdates

65. Preapproval and postapproval evidence on drugs for multiple sclerosis (Abstract)

Preapproval and postapproval evidence on drugs for multiple sclerosis To review the evidence supporting the European Union marketing authorization of drugs for multiple sclerosis (MS) and assess how far postmarketing research addresses information gaps at the time of approval.Through its database, we identified drugs approved by the European Medicines Agency and gathered data on pivotal trials from the European Public Assessment Reports and corresponding publications. We searched Medline

2018 EvidenceUpdates

66. Practice Guideline Recommendations Summary: Disease-modifying Therapies for Adults with Multiple Sclerosis

Practice Guideline Recommendations Summary: Disease-modifying Therapies for Adults with Multiple Sclerosis AAN Summary of Practice Guideline for Clinicians Practice Guideline: Disease-modifying Therapies for Adults with Multiple Sclerosis AAN.com ©2018 American Academy of Neurology This is a summary of the American Academy of Neurology (AAN) publication, “Practice guideline recommendations: Disease-modifying therapies for adults with multiple sclerosis,” which was published in Neurology ® (...) online on April 23, 2018, and appears in the April 24, 2018, print issue. Please refer to the full guideline at AAN.com/guidelines for more information, including definitions of the classifications of evidence and recommendations. Starting Disease-modifying Therapy (DMT) Recommendations Starting: Recommendation 1 Rationale Receiving the diagnosis of multiple sclerosis (MS) is a stressful life event. 4,5 People receiving major diagnoses may not recall much of the information given to them at the time

2018 American Academy of Neurology

67. Comprehensive Systematic Review Summary: Disease-modifying Therapies for Adults with Multiple Sclerosis

Comprehensive Systematic Review Summary: Disease-modifying Therapies for Adults with Multiple Sclerosis 1 Practice guideline: Disease-modifying therapies for adults with multiple sclerosis Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology Alexander Rae-Grant, MD 1 ; Gregory S. Day, MD, MSc 2 ; Ruth Ann Marrie, MD, PhD 3 ; Alejandro Rabinstein, MD 4 ; Bruce A.C. Cree, MD, PhD, MAS 5 ; Gary S. Gronseth, MD 6 ; Michael Haboubi (...) of Multiple Sclerosis Centers, Hackensack, NJ 9. Department of Neuroscience, St. Luke’s University Health Network, Bethlehem, PA 10. Department of Neurology, School of Medicine, University of Virginia, Charlottesville 11. Consortium of Multiple Sclerosis Centers, Hackensack, NJ, and Department of Neurology, School of Medicine, Wayne State University, Detroit, MI 12. Department of Neurology, Keck School of Medicine, University of Southern California, Los Angeles 13. Neurology Department, Southern

2018 American Academy of Neurology

68. Randomised controlled trial of a self-guided online fatigue intervention in multiple sclerosis Full Text available with Trip Pro

Randomised controlled trial of a self-guided online fatigue intervention in multiple sclerosis Fatigue is a major disabling symptom in many chronic diseases including multiple sclerosis (MS), but treatment options are limited.Here, we tested the effectiveness of a self-guided , interactive, online fatigue management programme (ELEVIDA) based on principles of cognitive behavioural therapy (CBT) and related psychotherapeutic approaches (eg, mindfulness) for reducing fatigue in MS.Patients with MS

2018 EvidenceUpdates

69. The Use of Digital and Remote Communication Technologies as a Tool for Multiple Sclerosis Management: Narrative Review Full Text available with Trip Pro

The Use of Digital and Remote Communication Technologies as a Tool for Multiple Sclerosis Management: Narrative Review Despite recent advances in multiple sclerosis (MS) care, many patients only infrequently access health care services, or are unable to access them easily, for reasons such as mobility restrictions, travel costs, consultation and treatment time constraints, and a lack of locally available MS expert services. Advances in mobile communications have led to the introduction (...) of screening and assessment, disease monitoring and self-management, treatment and rehabilitation, and advice and education. We review each solution, focusing on any clinical evidence supporting their use from prospective trials (including ASSESS MS, Deprexis, MSdialog, and the Multiple Sclerosis Performance Test) and consider the opportunities, barriers to adoption, and potential pitfalls of eHealth technologies in routine health care.©Martin Marziniak, Giampaolo Brichetto, Peter Feys, Uta Meyding-Lamadé

2018 JMIR rehabilitation and assistive technologies

70. Chronic Cerebro-Spinal Venous Insufficiency in Multiple Sclerosis: Is It the End? Full Text available with Trip Pro

Chronic Cerebro-Spinal Venous Insufficiency in Multiple Sclerosis: Is It the End? 29629362 2018 11 14 2288-7970 34 1 2018 Mar Vascular specialist international Vasc Specialist Int Chronic Cerebro-Spinal Venous Insufficiency in Multiple Sclerosis: Is It the End? 16-18 10.5758/vsi.2018.34.1.16 Rasman Alessandro A Department of Political and Social Sciences, University of Trieste, Trieste, Italy. eng Journal Article 2018 03 31 Korea (South) Vasc Specialist Int 101633116 2288-7970 Conflict

2018 Vascular specialist international

71. Multiple sclerosis. (Abstract)

Multiple sclerosis. Multiple sclerosis continues to be a challenging and disabling condition but there is now greater understanding of the underlying genetic and environmental factors that drive the condition, including low vitamin D levels, cigarette smoking, and obesity. Early and accurate diagnosis is crucial and is supported by diagnostic criteria, incorporating imaging and spinal fluid abnormalities for those presenting with a clinically isolated syndrome. Importantly (...) , there is an extensive therapeutic armamentarium, both oral and by infusion, for those with the relapsing remitting form of the disease. Careful consideration is required when choosing the correct treatment, balancing the side-effect profile with efficacy and escalating as clinically appropriate. This move towards more personalised medicine is supported by a clinical guideline published in 2018. Finally, a comprehensive management programme is strongly recommended for all patients with multiple sclerosis, enhancing

2018 Lancet

72. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. (Abstract)

Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. No treatment has consistently shown efficacy in slowing disability progression in patients with secondary progressive multiple sclerosis (SPMS). We assessed the effect of siponimod, a selective sphingosine 1-phosphate (S1P) receptor1,5 modulator, on disability progression in patients with SPMS.This event-driven and exposure-driven, double-blind, phase 3 trial was done at 292 (...) hospital clinics and specialised multiple sclerosis centres in 31 countries. Using interactive response technology to assign numbers linked to treatment arms, patients (age 18-60 years) with SPMS and an Expanded Disability Status Scale score of 3·0-6·5 were randomly assigned (2:1) to once daily oral siponimod 2 mg or placebo for up to 3 years or until the occurrence of a prespecified number of confirmed disability progression (CDP) events. The primary endpoint was time to 3-month CDP. Efficacy

2018 Lancet Controlled trial quality: predicted high

73. Exploring cued and non-cued motor imagery interventions in people with multiple sclerosis: a randomised feasibility trial and reliability study Full Text available with Trip Pro

Exploring cued and non-cued motor imagery interventions in people with multiple sclerosis: a randomised feasibility trial and reliability study Motor imagery (MI) is increasingly used in neurorehabilitation to facilitate motor performance. Our previous study results demonstrated significantly improved walking after rhythmic-cued MI in people with multiple sclerosis (pwMS). The present feasibility study was aimed to obtain preliminary information of changes in walking, fatigue, quality of life (...) ). Descriptive statistics were reported for all outcomes. Primary outcomes were walking speed (Timed 25-Foot Walk) and walking distance (6-Minute Walk Test). Secondary outcomes were recruitment rate, retention, adherence, acceptability, adverse events, MI ability (Kinaesthetic and Visual Imagery Questionnaire, Time-Dependent MI test), fatigue (Modified Fatigue Impact Scale) and QoL (Multiple Sclerosis Impact Scale-29). The reliability of a gait analysis system used to assess gait synchronisation with music

2018 Archives of physiotherapy Controlled trial quality: predicted high

74. EMA urgently reviewing multiple sclerosis medicine Zinbryta following cases of inflammatory brain disorders

EMA urgently reviewing multiple sclerosis medicine Zinbryta following cases of inflammatory brain disorders EMA urgently reviewing multiple sclerosis medicine Zinbryta following cases of inflammatory brain disorders | European Medicines Agency Search Search Menu EMA urgently reviewing multiple sclerosis medicine Zinbryta following cases of inflammatory brain disorders Press release 02/03/2018 Medicine to be voluntarily withdrawn from the market by the company The European Medicines Agency (EMA (...) ) has started an urgent review of the multiple sclerosis medicine Zinbryta (daclizumab) following 7 cases of serious inflammatory brain disorders in Germany, including encephalitis and meningoencephalitis, and one case in Spain. In parallel to the start of the review, the company that markets Zinbryta (Biogen Idec Ltd) has informed EMA of its intention to voluntarily withdraw the medicine's . Doctors in the EU will be contacted directly in the coming days with further information. Until then EMA

2018 European Medicines Agency - EPARs

75. EMA recommends immediate suspension and recall of multiple sclerosis medicine Zinbryta

EMA recommends immediate suspension and recall of multiple sclerosis medicine Zinbryta EMA recommends immediate suspension and recall of multiple sclerosis medicine Zinbryta | European Medicines Agency Search Search Menu EMA recommends immediate suspension and recall of multiple sclerosis medicine Zinbryta Press release 07/03/2018 Evidence indicates risk of serious inflammatory brain disorders The European Medicines Agency (EMA) has recommended the immediate suspension and recall (...) of the multiple sclerosis medicine Zinbryta (daclizumab beta) following 12 reports of serious inflammatory brain disorders worldwide, including encephalitis and meningoencephalitis. Three of the cases were fatal. A preliminary review of the available evidence indicates that immune reactions observed in the reported cases may be linked to the use of Zinbryta. Zinbryta may also be linked to severe immune reactions affecting several other organs. To protect patients' health, EMA is recommending the immediate

2018 European Medicines Agency - EPARs

76. Randomized Controlled Trial to Examine the Impact of Aquatic Exercise Training on Functional Capacity, Balance, and Perceptions of Fatigue in Female Patients With Multiple Sclerosis (Abstract)

Randomized Controlled Trial to Examine the Impact of Aquatic Exercise Training on Functional Capacity, Balance, and Perceptions of Fatigue in Female Patients With Multiple Sclerosis To assess the effects of an 8-week aquatic exercise training program on functional capacity, balance, and perceptions of fatigue in women with multiple sclerosis (MS).Randomized controlled design.Referral center of an MS society.Women (N=32; mean age ± SD, 36.4±8.2y) with diagnosed relapsing-remitting MS. After

2018 EvidenceUpdates

77. Evidenced-Based Cognitive Rehabilitation for Persons With Multiple Sclerosis: An Updated Review of the Literature From 2007 to 2016 (Abstract)

Evidenced-Based Cognitive Rehabilitation for Persons With Multiple Sclerosis: An Updated Review of the Literature From 2007 to 2016 To update the clinical recommendations for cognitive rehabilitation of people with multiple sclerosis (MS), based on a systematic review of the literature from 2007 through 2016.Searches of MEDLINE, PsycINFO, and CINAHL were conducted with a combination of the following terms: attention, awareness, cognition, cognitive, communication, executive, executive function

2018 EvidenceUpdates

78. Efficacy of Balance and Eye-Movement Exercises for Persons With Multiple Sclerosis (BEEMS) (Abstract)

Efficacy of Balance and Eye-Movement Exercises for Persons With Multiple Sclerosis (BEEMS) To determine whether a multifaceted vestibular-related rehabilitation program (Balance and Eye-Movement Exercises for Persons with Multiple Sclerosis; BEEMS) improves balance in persons with MS and whether there are differences in outcomes based on brainstem/cerebellar lesion involvement.A 2-arm, examiner-blinded, stratified (involvement vs no involvement of brainstem/cerebellar structures), randomized (...) , p < 0.0001), SF-36 Mental (3.9, 0.70-7.16, p = 0.02), and SF-36 Physical (3.2, 0.79-5.62, p = 0.01) scores. From baseline to 6 weeks, BEEMS participants with brainstem/cerebellar lesion involvement experienced greater improvements compared to those without in CDP-SOT composite (5.26, 0.34-10.2, p = 0.04) and MFIS total (-7.6, -14.0 to -1.33, p = 0.02) scores.BEEMS improved multiple outcomes regardless of whether brainstem/cerebellar lesions were present, supporting the generalizability of BEEMS

2018 EvidenceUpdates

79. Diagnosis and Treatment of Multiple Sclerosis: Guidelines

Diagnosis and Treatment of Multiple Sclerosis: Guidelines Diagnosis and Treatment of Multiple Sclerosis: Guidelines | CADTH.ca Find the information you need Diagnosis and Treatment of Multiple Sclerosis: Guidelines Diagnosis and Treatment of Multiple Sclerosis: Guidelines Published on: January 3, 2018 Project Number: RA0941-000 Product Line: Research Type: Other Diagnostics Report Type: Reference List Result type: Report Question What are the evidence-based guidelines for the full spectrum (...) of care (including diagnosis and treatment) of patients with multiple sclerosis? Key Message One evidence-based guideline was identified regarding the full spectrum of care (including diagnosis and treatment) of patients with multiple sclerosis. Tags multiple sclerosis, nervous system Files Rapid Response Reference List Published : January 3, 2018 Follow us: © 2019 Canadian Agency for Drugs and Technologies in Health Get our newsletter:

2018 Canadian Agency for Drugs and Technologies in Health - Rapid Review

80. Fampridine (Fampyra) in cases of multiple sclerosis (MS)

Fampridine (Fampyra) in cases of multiple sclerosis (MS) Fampridine (Fampyra®) in cases of multiple sclerosis (MS) | Report | National Health Care Institute You are here: Fampridine (Fampyra®) in cases of multiple sclerosis (MS) Search within English part of National Health Care Institute Search Fampridine (Fampyra®) in cases of multiple sclerosis (MS) Zorginstituut Nederland carried out an assessment of the medicinal product fampridine (Fampyra®). Based on the outcomes of the assessment

2018 National Health Care Institute (Zorginstituut Nederland)